Identification of the Zinc Finger Protein ZRANB2 as a Novel Maternal Lipopolysaccharide-binding Protein That Protects Embryos of Zebrafish against Gram-negative Bacterial Infections

Xia Wang1, Xiaoyuan Du1, Hongyan Li1, and Shicui Zhang1,2

From the 1Institute of Evolution and Marine Biodiversity and the Department of Marine Biology, Ocean University of China, Qingdao 266003, China and the 2Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266003, China

Zinc finger ZRANB2 proteins are widespread in animals, but their functions and mechanisms remain poorly defined. Here we clearly demonstrate that ZRANB2 is a newly identified LPS-binding protein present abundantly in the eggs/embryos of zebrafish. We also show that recombinant ZRANB2 (rZRANB2) acts as a pattern recognition receptor capable of identifying the bacterial signature molecule LPS as well as binding the Gram-negative bacteria Escherichia coli, Vibrio anguillarum, and Aeromonas hydrophila and functions as an antibacterial effector molecule capable of directly killing the bacteria. Furthermore, we reveal that N-terminal residues 11–37 consisting of the first ZnF_RBZ domain are indispensable for ZRANB2 antimicrobial activity. Importantly, microinjection of rZRANB2 into early embryos significantly enhanced the resistance of the embryos against pathogenic A. hydrophila challenge, and this enhanced bacterial resistance was markedly reduced by co-injection of anti-ZRANB2 antibody. Moreover, precipitation of ZRANB2 in the embryo extracts by preincubation with anti-ZRANB2 antibody caused a marked decrease in the antibacterial activity of the extracts against the bacteria tested. In addition, the N-terminal peptide Z1/37 or Z11/37 with in vitro antibacterial activity also promoted the resistance of embryos against A. hydrophila, but the peptide Z38/198 without in vitro antibacterial activity did not. Collectively, these results indicate that ZRANB2 is a maternal LPS-binding protein that can protect the early embryos of zebrafish against pathogenic attacks, a novel role ever assigned to ZRANB2 proteins. This work also provides new insights into the immunological function of the zinc finger proteins that are widely distributed in various animals.

Embryos of most mammalian species including our human being develop in the uterus inside the mother’s body and are thus well protected from pathogenic attacks. By contrast, the eggs of most fish are released and fertilized externally, and the resulting embryos/larvae are exposed to a hostile aquatic environment full of potential pathogens capable of causing various types of diseases (1). For example, the bacterium Flavobacterium psychrophilum has been shown to be the cause of a bacterial cold water disease that can affect salmonids ranging from yolk sac to yearling fish (2), and the virus Herpesvirus ictaluri is the cause of channel catfish virus disease, an acute viremia, which may result in high mortality and stunting of fry in juvenile channel catfish (3). Recently, it has been shown that exposure of salmon fry and juveniles to the Gram-negative bacterium Yersinia ruckeri causes the occurrence of enteric redmouth disease, leading to 60% mortality (4). However, early developing fish embryos/larvae have little or only limited ability to synthesize immune relevant molecules endogenously, and their lymphoid organs are not fully formed (5, 6). Furthermore, the early embryonic developmental stage is one of the most vulnerable periods in the fish life history (7), making the embryos more susceptible to invading pathogens. How fish embryos/larvae survive the pathogenic attacks in such a hostile environment is an intriguing and thus far unsolved question.

Fish eggs are in most cases cleidoic, i.e. in a closed free-living system post-fertilization; they are therefore supposed to depend upon the maternal provision of immune relevant molecules for protection against potential pathogens before full maturation of adaptive immune system (8). In the past 2 decades, the massive increase in aquaculture has put a greater emphasis on studies of the immune system and defense mechanisms against diseases associated with fish. As a result, a great progress has been made in recent years on the defense roles of maternally derived factors in embryos and larvae in fishes. It has been shown that maternal IgM is able to be transferred from mother to offspring in several fish species (9–20). Likewise, maternal transfer of the innate immune factors including lectins (21–25), lysozymes (26–28), and the vitellogenin-derived yolk proteins phosvitin and lipovitellin (29, 30) to offspring has

---

* This work was supported by Grants 31372505 and U1401211 from the National Natural Science Foundation of China, by Grant 201562029 from the Fundamental Research Funds for Central Universities, and by the Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, China. All experimental animals were treated in accordance with the guidelines of the Laboratory Animal Administration Law of China (permit number SD2007695) as approved by the Ethics Committee of the Laboratory Animal Administration of Shandong province. The authors declare that they have no conflicts of interest with the contents of this article.

† This work contains supplemental Figs. S1–S4 and Table S1.

1 To whom correspondence may be addressed: Institute of Evolution and Marine Biodiversity and Dept. of Marine Biology, Ocean University of China, Qingdao 266003, China. Tel.: 86-532-82032092; E-mail: hongyan@ouc.edu.cn.

2 To whom correspondence may be addressed: Institute of Evolution and Marine Biodiversity and Dept. of Marine Biology, Ocean University of China, Qingdao 266003, China. Tel.: 86-532-82032787; E-mail: sczhang@ouc.edu.cn.
ZRANB2, a Novel Maternal LPS-binding Protein

also been reported in different teleost species. Moreover, many of the complement components in fish, including C3, Bf, CD59, and C1q, are transferred from mothers to eggs at either the protein level or the mRNA level (31–36). Despite the enormous progress already made, we still have no idea how many maternal immune relevant factors are present in fish eggs, and the search for novel maternal immune molecules in fish eggs remains in its infancy. In this study, we have demonstrated that ZRANB2 is a newly identified maternal immune factor that can protect the embryos/larvae of zebrafish against Gram-negative bacterial infections. ZRANB2, originally identified from rat renal juxtaglomerular cells by Karginova et al. (37), has been isolated from a variety of vertebrates, including humans, mouse, rat, chicken, amphibians, and fish, and shown to be highly conserved among these species. Prior studies show that ZRANB2 proteins are co-immunoprecipitated with mRNAs and colocalized with the splicing factors SMN, U1–70K, U2AF35, and SC35, implying that ZRANB2 is a novel component of spliceosomes (38, 39). Recently, ZRANB2 has been characterized as a novel Smad-binding protein that suppresses bone morphogenetic protein (BMP) signaling (40) and is suggested to be a molecule associated with tumor development in mammals (41). Our study is thus the first report to show that ZRANB2 plays an immunological role in animals. This provides a new angle for the study of the immune functions and mechanisms of zinc finger proteins that are widely present in various animals.

Materials and Methods

Fish and Embryos—Wild-type zebrafish Danio rerio were purchased from a local fish dealer and maintained in the containers with well aerated tap water at 27 ± 1 °C. The fishes were fed with live bloodworms and fish flakes (TetraMin) twice a day. Sexually mature D. rerio were placed in the late evening at a female to male ratio of 2:1, and the naturally fertilized eggs were collected early the next morning and cultured at 27 ± 1 °C until use.

Isolation of LPS-bound Proteins and Mass Spectrometric Analysis—Lipopolysaccharide-conjugated affinity resin was prepared by coupling LPS (Sigma) from Escherichia coli O55:B5 with CNBr-activated Sepharose CL-4B (GE Healthcare) according to the manufacturer’s instructions. A total of 300 embryos collected at cell stages 64 to 128 were washed three times with sterilized distilled water, homogenized, and centrifuged at 5000 × g at 4 °C for 10 min. The supernatant was filtered through a 0.2-mm pyrogen-free filter to remove insoluble substances. After the addition of protease inhibitors, the supernatant was loaded onto the column, which had been pre-equilibrated with the initial buffer (10 mM Tris–HCl with 150 mM NaCl, pH 7.4) and incubated at 4 °C overnight. The column was washed with at least 10 column volumes of the initial buffer to remove the impurities. To recover proteins from the affinity matrix, the column was eluted with the elution buffer (4 M urea in 10 mM Tris–HCl, pH 7.4) as described by Chiou et al. (42). The effluent fractions containing the adsorbed proteins were pooled, desalted by gel filtration on a Sephadex G-25 column, and then concentrated with an Ultrafree-MC 5,000 nominal molecular weight filter unit (Millipore). The entire isolation procedure was performed at 4 °C. The LPS-bound proteins obtained were separated by SDS-PAGE and visualized by silver staining according to the methods of Minoda et al. (43) and Choi et al. (44). For mass spectrometric analysis, the protein bands visualized with silver staining were cut from gels and digested with trypsin (sequencing grade, Promega). MALDI/TOF MS analysis was performed on a Bruker Ultraflex MALDI/TOF MS mass spectrometer (Bremen, Germany) and searched against the nonredundant protein sequence database of the National Center for Biotechnology Information (NCBI) using the Mascot search engine (Matrix Science).

Western Blotting—MALDI/TOF MS analysis revealed that one of the proteins was ZRANB2, which is highly conserved among different species (see below). To examine the distribution of ZRANB2 in the different tissues and at the different developmental stages, the kidney, heart, liver, spleen, gut, muscle, gill, eye, ovary, testis, brain, skin, and tail were dissected out of zebrafish, and the newly fertilized eggs and embryos were collected at 12 and 24 h post-fertilization (hpf). All the samples were homogenized in PBS, pH 7.5, using a Polytron and sonicator, and the homogenates were centrifuged at 5,000 × g at 4 °C for 10 min. The protein concentration of the supernatants was determined using a bicinchoninic acid protein assay kit (ComWin Biotech). The supernatants were loaded onto and run on a 12% SDS-PAGE. The proteins on the gel were electroblotted onto PVDF membrane (Amersham Biosciences) by a semi-dry technique, and the blotted membranes were blocked with 4% bovine serum albumin (BSA) in PBS, pH 7.4, at room temperature for 2 h followed by incubation with rabbit anti-human ZRANB2 antibody (ZNF265 antibody, N-terminal region, ARP37747_T100) diluted 1: 800 with PBS, pH 7.4, at 4 °C overnight. The antibody was prepared from the peptide RCGREKTTTEAKMKKAGGTIEKGTLAEKARGLFSANDWQCKTCSNVNWR, which shares 98% conservation with the corresponding sequence of zebrafish ZRANB2 (Aviva Systems Biology). After a thorough washing in PBS, pH 7.4, containing 0.1% Tween 20, the membranes were incubated in horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (ComWin Biotech) diluted 1:2000, at room temperature for 3 h. The bands were visualized using DAB (3,3′N-diaminobenzidine tetrahydrochloride) (ComWin Biotech).

Immunohistochemistry—To examine the localization of ZRANB2 in cells, the embryos at desired stages were fixed in 4% paraformaldehyde in PBS overnight and frozen in prechilled acetone at −20 °C for 30 min. The embryos were washed four times with PBS containing 0.5% Triton X-100 (PBST), blocked in PBST with 5% sheep serum, 1% BSA, and 1% dimethylsulfoxide for about 2 h, and then incubated with human anti–rabbit ZRANB2 antibody diluted 1:500 at 4 °C overnight. After washing four times with PBST for at least 1 h, the embryos were incubated in PBST with 5% sheep serum, 1% BSA, 1% dimethyl sulfoxide, and goat anti–rabbit Alexa 488 antibody diluted 1:200 at 4 °C overnight. For control, the embryos were similarly washed and incubated with rabbit preimmune serum. To stain

3 The abbreviations used are: hpf, hours post-fertilization; qRT-PCR, semi-quantitative real time-PCR; WISH, whole-mount in situ hybridization; r, recombinant (e.g. rZRANB2); PRR, pattern recognition receptor; PDB, Protein Data Bank.
the nuclei, the embryos were counterstained with 1 μg/ml 4’,6-
diamidino-2-phenylindole (DAPI) in PBS for 10 min, washed in PBST for 10 min, and stored at 4 °C. The embryos/larvae were observed and photographed under a Leica confocal microscope.

In parallel, 24-hpf larvae were fixed in 4% polyformaldehyde in PBS and precipitated in a 30% sucrose solution at 4 °C overnight. Subsequently, they were embedded in optical cutting temperature compound, and sections were cut at 14 μm thickness at −20 °C (Leica). The sections were stained as described above, observed, and photographed under a Leica confocal microscope.

Cloning and Sequencing of Zebrafish zranb2—A total of 60 embryos/larvae of zebrafish was collected at about the 128-cell stage and ground in RNAiso Plus (TaKaRa). Total RNA were isolated from the ground samples according to the manufacturer’s instructions (Omega). After digestion with recombinant DNase I (RNase-free) (TaKaRa) to eliminate genomic contamination, the cDNA were synthesized with a reverse transcription kit (TaKaRa) with an oligo(dT) primer. The reaction was carried out at 42 °C for 1 h and inactivated at 75 °C for 15 min. The cDNA were stored at −20 °C till used.

Based on the sequence of zebrafish zranb2 (AAH52752.1) on NCBI, a primer pair, zranb2S and zranb2A, specific for zranb2 (Table 1), was designed using the Primer Premier program, version 5.0, and used for PCR to amplify the ZRANB2 cDNA using the RNA isolated above. The PCR protocol was as follows: an initial denaturation at 94 °C for 5 min followed by 37 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 40 s and a final extension at 72 °C for 7 min. The amplification product was cloned into the pGEM-T vector (Tiangen Biotech) following the manufacturer’s instructions and transformed into Trans 5α bacteria (TransGen Biotech). The DNA inserts were sequenced to verify for authenticity.

Homology, Phylogenetics, and Synteny Analyses—The ZRANB2 cDNA obtained was analyzed for coding probability with the DNASTAR software package, version 5.0, and the protein domain analyzed using the SMART program. The signal peptide prediction was conducted using the Signal P 3.0 server, and the molecular mass and isoelectronic point (pI) of the mature peptide were determined using ProtParam. The nuclear localization signal was predicted by PSORT II, and the three-dimensional structure prediction was performed by SWISS-MODEL online software at the Expert Protein Analysis System (EPPAS) server. The reliability of each node was estimated by bootstrapping with 1000 replications. Chromosomal locations of human (Homo sapiens), cow (Bos taurus), mouse (Mus musculus), frog (Xenopus tropicalis), and zebrafish (D. rerio) zranb2 genes were obtained from the Sequence Viewer and Ensembl genome browser.

Assay for Expression Patterns of zranb2—To detect the expression patterns of zranb2 in different tissues and at different developmental stages, the tissues including the kidney, heart, liver, spleen, gut, muscle, gill, eye, ovary, testis, brain, skin, and tail as well as the embryos/larvae, including the newly fertilized eggs, 4-, 16-, and 256-cell-stage embryos (~1, 1.5, and 2.5 hpf), high blastula-stage embryos (~3.5 hpf), 50% epiboly-stage embryos (~5 hpf), 10-somite-stage embryos (~15 hpf), 2-day-old larvae, and 3-day-old larvae, were sampled, ground in RNAiso Plus (TaKaRa), and stored at −70 °C until use. RNA extraction and cDNA synthesis were performed as described above. The semiquantitative real-time PCR (qRT-PCR) was performed in a final volume of 20 μl of the reaction mixture consisting of 10 μl of SYBR Premix Ex Taq™ (Tli RNase H Plus), 0.4 μl of ROX reference dye II, 0.5 μl of template, and each the sense and antisense primers (200 nm), qzranb2S and qzranb2A, specific for zranb2, designed using the Primer Premier program. The β-actin gene was chosen as the reference for internal standardization. All of the qRT-PCR experiments were conducted in triplicate and repeated three times. The amplification was performed on an ABI 7500 real-time PCR system (Applied Biosystems) initially at 95 °C for 15 s followed by 40 cycles of 95 °C for 5 s, 60 °C for 15 s, and 72 °C for 35 s. The expression levels of zranb2 relative to that of the β-actin gene were calculated by the comparative Ct method (46).

Whole-mount In Situ Hybridization (WISH)—The embryos/larvae were collected at the 2-cell stage, 256-cell stage, 50% epiboly stage, 10-somite stage, 1, 2, 3, and 5 days post-fertilization. A fragment of zranb2 was PCR-amplified using the primer pair wzranb2S and wzranb2A (Table 1) and subcloned into vector pGEM-T. The constructed vector was digested by the Ncol enzyme, and the zranb2-specific antisense probe labeled with digoxigenin-linked nucleotides was synthesized by Sp6 RNA polymerase. WISH was performed as described by C. Thisse and B. Thisse (47). Embryos/larvae were fixed and permeabilized before being soaked in the digoxigenin-labeled probe. After washing away the excess probe, the hybrids were detected by immunohistochemistry using an alkaline phosphatase-conjugated antibody against digoxigenin and a nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) substrate. The embryos/larvae were observed and photographed under a stereomicroscope (Nikon).

Expression and Purification of rZRANB2—The cDNA encoding complete ZRANB2 was amplified by PCR using the sense primer zranb2S (BamHI site is underlined) and the antisense primer zranb2A (HindIII site is underlined) (Table 1). The reaction was carried out under the following conditions: initial denaturation at 94 °C for 5 min followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s, extension at 72 °C for 40 s, and an additional extension at 72 °C for 7 min. The PCR products were digested with BamHI and HindIII and subcloned into the PET28a expression vector (Novagen, Darmstadt, Germany) digested previously with the same restriction enzymes. The inserts were verified by DNA sequencing, and the expression constructs were designated pET28a/zranb2.

The cells of E. coli BL21(DE3) were transformed with the plasmid pET28a/zranb2 and then cultured in LB broth containing 100 μg/ml kanamycin, which is a protein biosynthesis
ZRANB2, a Novel Maternal LPS-binding Protein

inhibitor combining with 30s ribosome and can cause mRNA password misreading (The plasmid pET28a/zranb2 is resistant to kanamycin, and thus E. coli BL21 with the plasmid pET28a/ zranb2 can readily synthesize the protein). The cultures were incubated in ZYM-0.8G for about 6 h, diluted at 1:100 with ZYM-5052, and then subjected to further incubation overnight at 37 °C. The bacterial cells were harvested by centrifugation at 5,000 × g at 4 °C for 10 min, resuspended in ice-cold lysis buffer (50 mM Tris-HCl containing 100 mM NaCl, pH 7.5), and sonicated on ice. The homogenate was centrifuged at 12,000 × g at 4 °C for 30 min, and the supernatant was collected. The protein rZRANB2 was purified by nickel-nitrilotriacetic acid resin column (GE Healthcare). Purified rZRANB2 was analyzed by SDS-PAGE on a 12% gel and stained with Coomassie Brilliant Blue R-250. In parallel, the purified rZRANB2 was also characterized by Western blotting. Protein concentration was determined by the bicinchoninic acid method using BSA as a standard (ComWin Biotech).

Assay for Binding of rZRANB2 to LPS, Lipid A, and Bacteria—Both rZRANB2 and BSA were individually biotinylated with biotinamidohexanoic acid N-hydroxysuccinimide ester (NHS-LC-biotin; HEOWNS Biochem Technologies, Tianjin, China) as described by Zhang et al. (48). To verify the binding of rZRANB2 to LPS, 50 µl of 80 µg/ml LPS in 10 mM PBS, pH 7.4, was applied to each well of a 96-well microplate and air-dried at 25 °C overnight. The plate was incubated at 60 °C for 30 min to further fix the LPS, and the wells were each blocked with 200 µl of 1 mg/ml BSA in 10 mM PBS, pH 7.4, at 37 °C for 2 h. After washing four times with 200 µl of 10 mM PBS supplemented with 0.5% Tween 20, 50 µl of biotinylated rZRANB2 or BSA (0, 0.35, 0.7, 1.4, 3.5, 7, and 14 µg/ml) was added to each well. After incubation at room temperature for 3 h, the wells were each rinsed four times with 200 µl of 10 mM PBS supplemented with 0.5% Tween 20, and 100 µl of streptavidin-HRP (ComWin Biotech) diluted to 1:5000 with 10 mM PBS, pH 7.4, containing 1 mg/ml BSA was added to each well. After incubation at room temperature for 1 h, the wells were washed four times with 200 µl of 10 mM PBS supplemented with 0.5% Tween 20, added with 75 µl of 0.4 mg/ml O-phenylenediamine (Amresco) in a buffer consisting of 51.4 mM Na2HPO4, 24.3 mM citric acid, and 0.045% H2O2, pH 5.0, and reacted at 37 °C for 5 to 30 min. Subsequently, 25 µl of 2 M H2SO4 was added to each well to terminate the reaction, and the absorbance at 492 nm was monitored by a microplate reader (GENios Plus, TECAN).

LPS consists of lipid A and polysaccharides. Thus we tested whether rZRANB2 would bind to lipid A. A stock solution of lipid A purchased from Sigma was prepared by dissolving it in dimethyl sulfoxide, giving a concentration of 1 mg/ml. Aliquots of 50 µl of 80 µg/ml lipid A in 10 mM PBS, pH 7.4, were applied to each well of a 96-well microplate, air-dried in 25 °C, and processed as described above.

To test whether rZRANB2 has any lectin activity, aliquots of 50 µl of 80 µg/ml LPS in 10 mM PBS, pH 7.4, was applied to each well of a 96-well microplate and air-dried at 25 °C overnight. The plate was then incubated at 60 °C for 30 min to further fix the LPS, and the wells were each blocked with 200 µl of 1 mg/ml BSA in 10 mM PBS, pH 7.4, at 37 °C for 2 h. Meanwhile, aliquots of 50 µl of 3.5 µg/ml rZRANB2 or BSA (control) in 10 mM PBS, pH 7.4, containing different concentrations (0, 1.25, 2.5, 5, 10, and 20 µg/ml) of various sugars (d-glucose, d-mannose, d-galactose, GlcNAc, and N-acetyl-d-mannosamine) were preincubated at room temperature for 1 h and then added into each well. After incubation at room temperature for 3 h, the contents of each well were processed and measured as described above (49).

To examine whether rZRANB2 is able to bind to bacteria, aliquots of 150 µl of the Gram-negative bacteria E. coli, Vibrio anguillarum, and Aeromonas hydrophila and the Gram-positive bacteria Staphylococcus aureus, Bacillus subtilis, and Micrococcus luteus (1 × 104 cells/ml) were mixed with 300 µl of 500 µg/ml rZRANB2 in 20 mM Tris-HCl buffer, pH 7.5, or with the same volume of Tris-HCl buffer alone (control). The mixtures were incubated at 25 °C for 2 h, and the bacteria were collected by centrifugation at 5000 × g at room temperature for 10 min. After washing with 20 mM Tris-HCl, the bacterial pellets were resuspended in 20 mM Tris-HCl, giving a concentration of 2 × 107 cells/ml. Both the rZRANB2-treated bacteria and the nontreated bacteria as well as purified rZRANB2 were run on a 12% SDS-PAGE followed by Western blotting analysis using rabbit anti-human ZRANB2 antibody as the primary antibody. The binding of rZRANB2 to the Gram-negative bacteria was also assayed by the method of Li et al. (50). In brief, E. coli, V. anguillarum, and A. hydrophila were mixed with rZRANB2 labeled with fluorescein isothiocyanate (FITC) and observed under an Olympus BX51 fluorescence microscope. For control, FITC-labeled BSA instead of rZRANB2 was used.

Assay for Antibacterial Activity of rZRANB2 in Vitro—The bacteria E. coli and V. anguillarum were cultured in LB medium at 37 °C to mid-logarithmic phase and collected by centrifugation at 6000 × g at room temperature for 10 min. Similarly, A. hydrophila was cultured in tryptic soy broth medium at 28 °C to mid-logarithmic phase and collected by centrifugation. The antibacterial activity of rZRANB2 against E. coli and V. anguillarum was assayed by the method of Yao et al. (51). To test the effect of Zn2+ on antibacterial activity, aliquots of 100 µl of rZRANB2 solution (50 µg/ml) were first mixed either with 1 µl of 1 mM ZnCl2 plus 189 µl of the bacterial culture medium or with 1 µl of 100 mM EDTA (which is capable of chelating Zn2+) plus 89 µl of the bacterial culture medium and then mixed with 10 µl of E. coli or V. anguillarum suspension (105 cells/ml). The positive and negative controls were processed similarly, except that rZRANB2 was replaced by kanamycin (2 µg/ml) or BSA (50 µg/ml). All of the mixtures were added to the wells of a 96-well plate and cultured at 37 °C. Inhibition of bacterial growth in each well was determined at each time point by measuring the absorbance at 600 nm with a Multiskan MK3 microplate reader every hour. The experiments were performed in triplicate and repeated three times.

A colony formation assay was used to test the antimicrobial activity of rZRANB2 against the Gram-negative bacterium A. hydrophila and the Gram-positive bacteria S. aureus, B. subtilis, and M. luteus (51). In brief, 100 µl of 10, 20, and 100 µg/ml rZRANB2 dissolved in 20 mM Tris-HCl buffer, pH 7.5, was mixed with 89 µl of the bacterial culture medium, 1 µl of 1 mM ZnCl2, and 10 µl of an A. hydrophila, S. aureus, B. subtilis, or M. luteus suspension (8 × 104 cells/ml). To test the effect of
**ZRANB2, a Novel Maternal LPS-binding Protein**

Zn$^{2+}$ on antibacterial activity, 100 µl of 100 µg/ml rZRANB2 was first mixed either with 1 µl of 1 mM ZnCl$_2$ plus 189 µl of the bacterial culture medium or with 1 µl of 100 mM EDTA plus 89 µl of the bacterial culture medium and then mixed with 10 µl of an *A. hydrophila*, *S. aureus*, *B. subtilis*, or *M. luteus* suspension (10$^9$ cells/ml). The controls were processed similarly except that rZRANB2 was replaced by kanamycin and BSA. The mixtures were preincubated, with gentle stirring at 25 °C for 60 min and plated onto three agar plates (50 µl/plate). The percent of bacterial growth inhibition was calculated as follows: [number of colonies (control-test)/number of colonies (control)] × 100 ($n = 3$). The half-inhibitory concentration (IC$_{50}$) was defined as the lowest protein concentration at which the growth of the respective bacterium was 50% inhibited.

**Flow Cytometry—**Flow cytometry was used to measure the effect of rZRANB2 on the bacterial membranes of *E. coli*, *V. anguillarum*, and *A. hydrophila*. The collection and culture of the bacteria were as described above. After washing three times with PBS, pH 7.5, the bacterial pellets were suspended in PBS and adjusted to a density of 1 × 10$^8$ cells/ml, and then rZRANB2 was added to the bacterial suspensions, yielding final concentrations of 10 and 25 µg/ml for *E. coli* and 25 and 50 µg/ml for both *V. anguillarum* and *A. hydrophila*. In parallel, Triton X-100 and BSA were used instead of rZRANB2 for positive and negative controls. The mixtures were incubated at 28 °C for 2 h and fixed with 10 µM propidium iodide solution under dark conditions at 4 °C for 15 min. The bacterial cells stained by propidium iodide were examined using a FC500 MPL flow cytometer (Beckman). Data were analyzed using WinMDI, version 2.9, software (Scripps Research Inst., San Diego).

**Assay for Antibacterial Activity of ZRANB2 in Embryos/Larvae—**The 64–128-cell stage embryos of zebrafish were collected and washed three times with sterilized distilled water, homogenized, and centrifuged at 5000 × g at 4 °C for 10 min. As rZRANB2 showed conspicuous antibacterial activity against *E. coli*, *V. anguillarum*, and *A. hydrophila*, we wondered whether ZRANB2 would play any role in the immune defense in early embryos. First, we investigated the antibacterial activity of ZRANB2 in the embryo extracts. The antibacterial activity of the embryo extracts against *E. coli*, *V. anguillarum*, and *A. hydrophila* was assayed as described by Wang et al. (36). To precipitate ZRANB2 in the embryo extracts, 1 ml of the extracts was mixed with 0.5 µg of rabbit anti-human ZRANB2 antibody. For control, 1 ml of the embryo extracts was mixed with 0.5 µg of anti-β-actin antibody. Next, we assayed whether ZRANB2 had any ability to protect developing embryos in vivo. Fifty of the 8-cell stage embryos were dechorionated, microinjected into the yolk sac with 6 nl of sterilized PBS, pH 7.4 (blank control), anti-ZRANB2 antibody solution (0.33 ng), anti-actin antibody solution (0.33 ng), purified rZRANB2 solution (0.6 ng), or BSA solution (0.6 ng), and challenged 1 h later by injection of 6 nl of live *A. hydrophila* suspension (~500 cells). The mortality rate was recorded, and the cumulative mortality rate was calculated 24 h after the bacterial injection. To confirm the specificity of the antimicrobial activity of rZRANB2 in vivo, anti-ZRANB2 antibody was injected together with rZRANB2 into the embryos, which were then challenged by injection of live *A. hydrophila* (29). For control, the embryos were co-injected with anti-actin antibody and rZRANB2 and treated similarly.

To verify the killing of *A. hydrophila* by developing embryos, 8-cell stage embryos were dechorionated and microinjected with live *A. hydrophila* as described above. Five embryos were collected each time at 0, 12, and 24 h after the bacterial injection. The normal embryos were similarly collected as controls. The total DNAs were isolated from each embryo according to the method of Wang et al. (36) and used for PCR and qRT-PCR analyses. PCR and qRT-PCR were carried out, respectively, to amplify a specific region of the *A. hydrophila* 16s rRNA gene using the sense primer 16s rRNAs 5-AATCCGGCATTAGCC- CCTAC-3, antisense primer 16s rRNAs 5-ACCCCCACATC-TCAAGCAC-3, sense primer q16s rRNAs TGAAGGCGCTT- ACCATTGCGCAGATC, and antisense primer q16s rRNAs GCCGGTGTCTTATTTCTGCAGTAATG (Table 1), which were designed on the basis of the *A. hydrophila* 16s rRNA sequence (GenBank™ accession number DQ207728).

**Titration of ZRANB2 Content in Eggs and Embryos—**Exactly 120 embryos were collected at 0, 12, and 24 hpf, washed three times with sterilized 0.9% saline, homogenized, and centrifuged at 5000 × g at 4 °C for 5 min. The supernatants were pooled and used to measure the contents of ZRANB2 in the extracts by ELISA using rabbit anti-human ZRANB2 antibody. In brief, 200 µl of rabbit anti-human ZRANB2 antibody diluted at 1:2500 with 10 mM PBS, pH 7.4, was applied to each well of a 96-well microplate at 4 °C overnight. After washing three times with 200 µl of PBS supplemented with 0.5% Tween 20, 200 µl of the embryo extracts or rZRANB2 (0, 5, 10, 25, 50, 100, and 200 ng/ml) was added to each well and detected as above. The mean diameter of zebrafish eggs measured was 600 µm, and therefore each egg/embryo volume was ~1.1 × 10$^{-7}$ cm$^3$. Accordingly, the content of ZRANB2 in each egg/embryo was inferred as described by Liang et al. (52).

**Structure-Activity Assays—**To determine the structure-activity relationship, N-terminal deletion of ZRANB2 was carried out. The cDNA region encoding the C-terminal 161 residues 38–198 (Z$_{38/198}$ with the N-terminal 37 residues depleted) of ZRANB2 was amplified by PCR using the sense primer z38/198 1:2500 with 10 mM PBS, pH 7.4, was applied to each well of the expression vector plasmid pET28a/z38/198 (BamHI site is underlined) and the antisense primer z38/198/A. hydrophila ( HindIII site is underlined) (Table 1). Construction of the expression vector plasmid pET28a/z38/198 and its transformation into *E. coli* BL21 were performed as described above. The *E. coli* BL21 with pET28a/z38/198 was cultured in LB broth containing 50 µg/ml kanamycin overnight. The culture was diluted 1:100 with LB broth and subjected to further incubation until A$_{600}$ reached about 1.0 at 37 °C. The expression of rZ$_{38/198}$ was induced by adding isopropyl 1-thio-β-D-galactopyranoside to the culture at a final concentration of 0.1 mM, and then the culture was incubated at 28 °C for about 12 h. The protein rZ$_{38/198}$ was then purified and characterized. The antibacterial activity of Z$_{38/198}$ against *E. coli*, *V. anguillarum*, and *A. hydrophila* and its affinity to LPS were assayed as described above. As the polypeptide Z$_{38/198}$ lost nearly all antibacterial activity (see below), thus two peptides (purity > 99%) comprising the N-terminal 37 residues (Z$_{1/37}$) and the N-terminal 26 residues (Z$_{1/26}$), which consists of the ZnF_RBZ domain per se) of ZRANB2 were synthesized by Sangon Biotech (Shanghai, China) and
subjected to antibacterial activity and LPS binding assays. For the antibacterial activity assay of Z1/37 and Z11/37, LPS was biotinylated with NHS-LC-biotin instead of the peptides 4024 JOURNAL OF BIOLOGICAL CHEMISTRY 0.05 was considered significant. All of the data were expressed by one-way analysis of variance. The difference at least three times. Statistical analyses were performed using bioactivity were also microinjected into zebrafish embryos followed by antibacterial activity and LPS binding assays. For WISH-PCR, as described above, to test their ZRANB2 Is a LPS-binding Protein Stored in Early Embryos—

RESULTS

ZRANB2 Is a LPS-binding Protein Stored in Early Embryos—

The proteins eluted from the LPS-conjugated Sepharose CL-4B column were resolved by SDS-PAGE and silver-stained, and we identified two main bands (a and b) of ~38.9 and 22.7 kDa (Fig. 1a). MALDI/TOF MS analysis revealed that band a was ZNF365, consisting of 345 amino acids (data not shown), and band b was zinc finger Ran-binding domain (ZnF_RBZ)-containing protein 2, ZRANB2 (GenBank™ accession number AAH52752.1) consisting of 198 amino acids (Fig. 1b).

Western blotting showed that ZRANB2 was primarily present in the liver, muscle, eye, brain, ovary, and testis, with the level in the ovary being highest (Fig. 1c), suggesting that ZRANB2 was distributed mainly in the ovary. Accordingly, ZRANB2 was also detected in the fertilized eggs and the 12- and 24-h embryos (Fig. 1d). These data suggest that ZRANB2 is a LPS-binding protein stored maternally in the eggs/embryos of zebrafish.

**ZRANB2 Is Localized in Cytoplasm—** Immunohistochemical examination showed that ZRANB2 was localized predominantly in the blastoderm in 4-, 8-, 32-, and 128-cell stage embryos and in the epidermis and neural tube in the head of 24-hpf larvae, with little positive signal (green fluorescence) in the yolk sac (Fig. 2, a and b, B and C). In the 6-hpf embryos, ZRANB2 was clearly found to be distributed in the cytoplasm (Fig. 2a), indicating that ZRANB2 is a protein localized in the cytoplasm of embryonic cells.

**Structure, Phylogenetics, and Synteny of zranb2—** Zebrafish ZRANB2 cDNA obtained was 2044-bp long and contained an open reading frame of 597 bp coding for a protein of 198 amino acids with a calculated molecular mass of ~22.7 kDa and a pI of 4.36, a 5′-untranslated region of 63 bp, and a 3′-untranslated region of 166 bp (supplemental Fig. S1). Zebrafish ZRANB2 has eight highly conserved cysteine residues spaced appropriately to give rise to two ZnF RBZ domains (at residues 1–40 and 65–95; Fig. 3a) as well as the motifs NXXFXXRRXXXN and NXX-
WXRRXXXN of the RNA-binding region (supplemental Fig. S2), characteristic of known ZRANB2 proteins, but it lacks the typical nuclear localization signal (supplemental Table S1) and the C-terminal serine-rich domain (supplemental Fig. S2). Sequence alignment showed that zebrafish ZRANB2 was 79.2%, 80.3%, 80.6%, and 82.3% identical to mammalian, avian, amphibian, and teleost ZRANB2 at amino acid levels (supplemental Fig. S3). The structure prediction using the SWISS-MODEL online software revealed that the three-dimensional structures of the ZnF_RBZ domains of both zebrafish and human ZRANB2 consist mainly of β-sheets (Fig. 3b). The first ZnF_RBZ domains (at residues 1–40) of zebrafish and human ZRANB2 share a similar three-dimensional structure with a Zn$^{2+}$-binding site, whereas the second ZnF_RBZ domain (at residues 65–95) of zebrafish and human ZRANB2 are different in that the second ZnF_RBZ domain of zebrafish ZRANB2 has no Zn$^{2+}$-binding site (Fig. 3b).

The phylogenetic tree constructed using the available sequences of ZRANB2 proteins shows that zebrafish ZRANB2 is grouped together with other teleost ZRANB2 forming an independent clade branched from mammalian, avian, and amphibian counterparts. This well reflects the established phylogeny of chosen organisms. Syntenic analysis showed that zebrafish zranb2 is mapped onto chromosome 6 and closely linked to Negr1 and Ptger, which is similar to human, cow, mouse, and frog zranb2 (Fig. 3d). Additionally, the direction of zebrafish zranb2 relative to Negr1 and Ptger is comparable with that of human, cow, mouse, and frog zranb2 (Fig. 3d), implying that the linkage of zranb2 with Negr1 and Ptger is conserved from fish to humans.

**Tissue- and Stage-specific Expression of zranb2**—qRT-PCR showed that zranb2 is expressed primarily in the liver, muscle, eye, brain, ovary, and testis in a tissue-specific manner, with the most abundant expression in the ovary (Fig. 4a), consistent with the tissue-specific distribution of ZRANB2 (Fig. 1, c and d). As shown in Fig. 4b, zranb2 mRNA was abundant in the zygotes (0 hpf) but decreased continuously as development went forward, and from 15 hpf onward...
only slight mRNA was detected in the embryos/larvae. These findings indicate that the maternal \textit{zranb2} mRNA level is relatively higher in the fertilized eggs, which decreases with development.

As shown in Fig. 4c, pan-expression of \textit{zranb2} was observed in the embryos before segmentation stages (Fig. 4c, A–D), and then \textit{zranb2} mRNA was observed primarily in the head of 1- and 2-day-old larvae (Fig. 4c, E and F), which have the brain and eyes as the main organs in the head at this stage; but little signal was detected in 3- and 5-day-old larvae (Fig. 4c, G and H). This is basically consistent with the distribution of ZRANB2 protein in the embryos (Fig. 2). These findings suggest that ZRANB2 may play a role in early development, especially in the formation of the head including the brain and eyes.

\textbf{rZRANB2 Interacts with LPS, Lipid A, and Gram-negative Bacteria—} Zebrafish ZRANB2 was expressed in \textit{E. coli} BL21 (DE3) and purified by affinity chromatography on a nickel-nitrilotriacetic acid resin column. The purified recombinant protein, rZRANB2, yielded a single band of $\sim 27.6$ kDa on SDS-PAGE after Coomassie Blue staining, corresponding to the expected size (Fig. 5a). Western blotting analysis showed that the purified protein reacted with the rabbit anti-human ZRANB2 antibody, indicating that rZRANB2 was correctly expressed (Fig. 5b).

As shown in Fig. 5c, rZRANB2 interacted with LPS in a dose-dependent manner, whereas BSA used as negative control did not, confirming without a doubt that zebrafish ZRANB2 is indeed a LPS-binding protein. We then tested for whether rZRANB2 binds to lipid A, a core component of LPS. It was
found that rZRANB2 displayed an affinity to lipid A comparable with that of LPS (Fig. 5d), which agrees with the observations that zinc finger proteins have lipid binding activity (53, 54). Interestingly, the affinity of rZRANB2 to LPS was not inhibited by any of the sugars examined, even at a concentration as high as 20 mg/ml (Fig. 5e). Notably, the optical density of BSA in Fig. 5e was slightly higher than that in Fig. 5c and d. This superficial increase in OD value resulted from the difference in coloration time. The coloration time was about 10 min in Fig. 5c, d, whereas in Fig. 5e, the coloration time was extended to 30 min, thus leading to a deeper color and a greater OD value. Altogether, these findings indicate that rZRANB2 has little lectin activity. It is clear that zebrafish ZRANB2 may bind to LPS via lipid A.

Western blotting showed that rZRANB2 also bound to E. coli, V. anguillarum, and A. hydrophila (Fig. 5f). In addition, FITC-labeled rZRANB2 exhibited affinity to all of the Gram-negative bacteria tested (Fig. 5g). By contrast, rZRANB2 could not bind to the Gram-positive bacteria S. aureus, B. subtilis, or M. luteus (supplemental Fig. S4). These findings suggest that zebrafish rZRANB2 interacts only with Gram-negative bacteria, further strengthening the idea that ZRANB2 is a LPS-binding protein.

**Bactericidal Activity of rZRANB2**—As zebrafish ZRANB2 is a LPS-binding protein, we thus wanted to know whether it has antibacterial activity. As shown in Fig. 6, the growth of the Gram-negative bacteria E. coli, V. anguillarum, and A. hydrophila was inhibited by rZRANB2 in a dose-dependent manner when Zn²⁺ was present (Figs. 6, a–c, and 9a), indicating that in addition to the LPS binding activity, rZRANB2 can also inhibit Gram-negative bacterial growth. When the concentration of rZRANB2 was at 10 μg/ml or above, the growth of all the Gram-negative bacteria tested was significantly suppressed. By contrast, removal of Zn²⁺ completely abolished the antibacterial activity of rZRANB2 against E. coli, V. anguillarum, and A. hydrophila, suggesting the dependence of antibacterial activity of rZRANB2 upon Zn²⁺ (Fig. 6, a–c). It was also shown that rZRANB2 did not inhibit the growth of the Gram-positive bacteria S. aureus, B. subtilis, and M. luteus even in the presence of Zn²⁺ (supplemental Fig. S4), suggesting that ZRANB2 can specifically inhibit the growth of Gram-negative bacteria but not Gram-positive bacteria.

Flow cytometry revealed that a few of the E. coli, V. anguillarum, and A. hydrophila cells treated with BSA, or non-treated, showed a propidium iodide fluorescent signal (Fig. 6d), indicating that they had intact and viable cell membranes. By contrast, a significant proportion of the E. coli, V. anguillarum, and A. hydrophila cells treated with rZRANB2 displayed a fluorescent signal, and the number of cells with a fluorescent signal increased with increasing doses of rZRANB2, indicating that their cell membranes were no longer intact and became permeable to propidium iodide. These findings suggest that
rZRANB2 is able to destroy the membrane integrity of *E. coli*, *V. anguillarum*, and *A. hydrophila* cells.

**ZRANB2 Is Involved in Antibacterial Defense of Early Embryos**—The protein concentration of the extracts prepared from 64–128-cell stage embryos was ~5 mg/ml. The embryo extracts showed conspicuous antimicrobial activity against *E. coli*, *V. anguillarum*, and *A. hydrophila*; this bacterial growth-inhibitory activity was significantly reduced by preincubation of the extracts with anti-human ZRANB2 antibody but not by preincubation with anti-actin antibody (Fig. 7, a–c). These findings suggest that ZRANB2 in the embryo extracts is a molecule capable of inhibiting bacterial growth.

To examine whether ZRANB2 plays the same role in vivo, 8-cell stage embryos were each microinjected with anti-ZRANB2 antibody to block ZRANB2 action followed by injection with live *A. hydrophila* (pathogenic to *D. rerio*). The majority (~94%) of the embryos injected with PBS, BSA, anti-actin antibody, anti-ZRANB2 antibody, rZRANB2, rZRANB2 plus anti-actin antibody, or rZRANB2 plus anti-ZRANB2 antibody developed normally, with the 24-h cumulative mortality rate being about 6% (Fig. 7d). Notably, the challenge with live *A. hydrophila* resulted in a significant increase in the mortality rate of the embryos injected with anti-ZRANB2 antibody (resulting in a decrease of ZRANB2), with a 24-h mortality rate of ~85.7%, whereas the same challenge caused only ~64.3, 65.0, and 66.0% mortality at 24 h in the embryos injected with either anti-actin antibody or BSA or PBS alone (Fig. 7d), indicating that blocking of ZRANB2 action in the embryos was able to reduce their anti-*A. hydrophila* activity. In comparison, the 24-h mortality rate of the embryos injected with rZRANB2 (resulting in an increase of ZRANB2) was reduced to ~53.3%, which is markedly lower than that of the embryos injected with...
anti-actin antibody or BSA or PBS alone, suggesting that the increased amount of ZRANB2 contributed to the protection of embryos against *A. hydrophila* attack. Moreover, the embryo protecting activity of rZRANB2 was apparently reduced by co-injection of anti-ZRANB2 antibody but not by co-injection of anti-actin antibody (24-h mortality rate being 84.3% versus 52.3%), thus implying the specificity of ZRANB2 antibacterial activity. All of these data suggest that ZRANB2 is involved in the antimicrobial defense of early embryos of zebrafish.

To prove the killing of live *A. hydrophila* by the embryos, both PCR and qRT-PCR were performed to amplify a specific region of the *A. hydrophila* 16s rRNA gene. As shown in Fig. 7, no band was observed in the control sample (from embryos without injected *A. hydrophila*), but intense bands were found in the embryos collected soon after the bacterial injection (0 h). The band intensities apparently decreased with time (at 12 and 24 h), suggesting the lysis of the bacterium by the embryos (Fig. 7, e). Similarly, the microinjection of anti-actin antibody into the embryos also failed to suppress the reduction of the band intensity at 12 and 24 h, i.e. *A. hydrophila* lysis continued in the embryos (Fig. 7, eB). By contrast, the injection of anti-ZRANB2 antibody into the embryos clearly suppressed the decrease in the band intensity during the initial 12 and 24 h (Fig. 7, eC), i.e. little *A. hydrophila* lysis took place in the embryos. This was further supported by the results of qRT-PCR (Fig. 7f), which showed that expression of the 16s RNA gene of *A. hydrophila* in the embryos injected with anti-actin antibody decreased significantly (*p* < 0.5), but its expression in the embryos injected with anti-ZRANB2 antibody did not (*p* > 0.5). These data suggest a clear correlation between ZRANB2 content and lysis of the bacterium in the early embryos.

ELISA analysis revealed that the concentrations of ZRANB2 in each of the newly fertilized eggs as well as in each of the 12- and 24-h embryos were about 10.0, 14.2, and 20.1 mg/ml, respectively. The increase of ZRANB2 in the 12- and 24-h embryos may be due to the translation of ZRANB2 mRNA stored in eggs during embryogenesis (Fig. 4b). rZRANB2 was able to significantly inhibit the growth of all the Gram-negative bacteria tested at a concentration of 10 μg/ml or above (Fig. 6, a–c), and thus the endogenous concentration of ZRANB2 in
ZRANB2, a Novel Maternal LPS-binding Protein

FIGURE 7. Antibacterial activities of ZRANB2 against *E. coli*, *V. anguillarum*, and *A. hydrophila* in vitro and in vivo. *a*, antimicrobial activity of the embryo extract against *E. coli*. *b*, antimicrobial activity of the embryo extract against *V. anguillarum*. *c*, antimicrobial activity of the embryo extract against *A. hydrophila*. *d*, the early (8-cell stage) embryos were first microinjected with PBS, BSA, anti-β-actin antibody (AcAb), anti-human ZRANB2 antibody (ZRANB2Ab), rZRANB2, and rZRANB2 plus AcAb or rZRANB2 plus ZRANB2Ab and then challenged by injection with live *A. hydrophila*. The development of the embryos was observed, and the cumulative mortality rate was calculated at 24 h after bacterial injection. *e*, PCR analysis of *A. hydrophila* 16s rRNA gene. The 8-cell stage embryos were microinjected with live *A. hydrophila*, and five embryos were collected each time at 0, 12, and 24 h after the bacterial injection. Total DNA was isolated from each embryo and used as the template to amplify the specific region of the *A. hydrophila* 16s rRNA gene. All of the PCR products were electrophoresed in 1% agarose, and the bands were recorded using the gel imaging system. *f*, embryos injected with *A. hydrophila* only; *B*, embryos injected with anti-β-actin antibody followed by injection with *A. hydrophila* only; *C*, embryos injected with anti-human ZRANB2 antibody followed by injection with *A. hydrophila*. *M*, marker; con, control; PBS, embryo extract; AcAb, anti-β-actin antibody; ZRANB2Ab, anti-human ZRANB2 antibody.

Each embryo is sufficient enough to kill potential pathogens in vivo, at least at the initial 24 hpf. Notably, ZRANB2 was apparently not distributed homogenously in the embryos but was restricted in the blastoderm of early embryos and in the epidermis and neural tube of larvae. Therefore, the concentration of ZRANB2 in these sites of the embryos is certainly higher than 10 μg/ml, which may greatly strengthen the antibacterial activity therein.

The N-terminal 11–37 Residues Are Critical for Antibacterial Activity of ZRANB2—The deletion of the N-terminal 37 residues resulted in an almost complete loss of the antibacterial activity of ZRANB2 against *E. coli*, *V. anguillarum*, and *A. hydrophila* (Figs. 8, a–d, and 9c), suggesting that the N-terminal 37 residues are important for antibacterial activity. This may be due to the fact that the deletion of the N-terminal 37 residues resulted in the loss of the Zn²⁺-binding site, and thus the remaining C-terminal 161 residues without a Zn²⁺-binding site may not form correct three-dimensional structures. By contrast, synthesized Z₁/₃⁷ and Z₁₁/₃⁷ both retained a large antibacterial activity against *E. coli*, *V. anguillarum*, and *A. hydrophila* in the presence of Zn²⁺ (Figs. 8, e–j, and 9b and d). Specifically, the IC₅₀ values of Z₁/₃⁷ and Z₁₁/₃⁷ against *A. hydrophila* were −9.3 and −8.5 μg/ml, respectively, which are just slightly lower than that (−9.7 μg/ml) of full-length rZRANB2. It is interesting to note that Z₃₈/₁₉₈ containing the second ZnF_RBZ domain had little antibacterial activity, whereas both Z₁/₃⁷ and Z₁₁/₃⁷ containing the first ZnF_RBZ domain retained the antibacterial activity. The reason for this difference is probably because the second ZnF_RBZ domain in ZRANB2 has no Zn²⁺-binding site (Fig. 3b). It is also notable that Z₁₁/₃⁷ and Z₁₁/₃⁷ possess affinity to LPS (Fig. 8, l and m), consistent with the fact that they both retained the antimicrobial activity, whereas Z₃₈/₁₉₈ lost the affinity to LPS (Fig. 8k), agreeing with the fact that it had little antimicrobial activity. These findings suggest that the antibacterial activity of Z₁₁/₃⁷ and Z₁₁/₃⁷, as well as rZRANB2, is related to their capacity to bind to LPS. Altogether, these data indicate that the N-terminal 37 residues, especially residues 11–37 comprising the first ZnF_RBZ
domain itself, are the core region indispensable for both anti-microbial activity and binding to LPS.

When the embryos were each microinjected with Z1/37, Z11/37, or Z38/198, approximately ∼94% of the embryos developed normally. By contrast, the challenge with live *A. hydrophila* caused a significant increase in the mortality rate of the embryos injected with Z38/198, PBS, or BSA, with a 24-h cumulative mortality rate of 66, 68.3, and 63.7%, respectively; but the same challenge induced only 51.3 and 47.7% cumulative mortality at 24 h in the embryos injected with Z1/37 or Z11/37 (Fig. 10). Moreover, the embryo-protecting role of Z1/37 and Z11/37 was counteracted by the co-injection of anti-ZRANB2 antibody but not by co-injection of anti-actin antibody (Fig. 10). It is thus clear that Z1/37 and Z11/37 with antimicrobial activity in vitro, are also involved in the antimicrobial activity of developing embryos, whereas Z38/198, with no antibacterial activity in vitro, exhibits no antibacterial activity in vivo.

**Discussion**

Information regarding the functions and mechanisms of ZRANB2 proteins remains rather limited to date. Here we clearly demonstrate that zebrafish ZRANB2 is a novel LPS-binding protein stored abundantly in the eggs/embryos. It can function as a pattern recognition receptor (PRR), which recognizes potential Gram-negative pathogens through interaction with LPS via lipid A. The nature of ZRANB2 may have an important physiological significance. Great advances have been made recently in identifying pattern recognition molecules, but few of them have been tested for their existence in early embryos (55). Our data show that ZRANB2 is a new PRR functioning in the eggs and early embryos.

**FIGURE 8.** Diagram showing zebrafish ZRANB2 truncation, analyses of bioactivity of Z1/37, Z11/37, and Z38/198 against *E. coli*, *V. anguillarum*, and *A. hydrophila*, and binding of Z1/37, Z11/37, and Z38/198 to LPS. a, diagram showing zebrafish ZRANB2 truncation. b–d, antibacterial activity of Z1/37 against *E. coli*, *V. anguillarum*, and *A. hydrophila*. e–g, antibacterial activity of Z38/198 against *E. coli*, *V. anguillarum*, and *A. hydrophila*. h–j, antibacterial activity of Z11/37 against *E. coli*, *V. anguillarum*, and *A. hydrophila*. k–m, binding of Z1/37, Z11/37, and Z38/198 to LPS. BSA was treated at the same concentrations as the control. All data were expressed as mean values ± S.D. (n = 3). The data are from three independent experiments performed in triplicate. The bars represent the mean ± S.D.
of zebrafish. However, it must be pointed out that ZRANB2 may function only when pathogens have penetrated the embryos/larvae, as it is localized in the cytoplasm.

An important part of innate immunity is that quite a few proteins show antibacterial activity in addition to having an immune recognition function. These proteins play essential roles in host nonspecific defenses by preventing or limiting infections via their capacity to recognize potential pathogens; most of these proteins also exert antibacterial effects by interacting with and destabilizing either the bacterial cell wall or the plasma membranes, leading to cell death eventually. Another important finding of our study is that ZRANB2 is not only a PRR capable of binding to Gram-negative bacteria but also an effector molecule capable of lysing pathogenic \textit{A. hydrophila}.

Because an injection of exogenous rZRANB2 into early embryos promotes their resistance to pathogenic \textit{A. hydrophila} challenge, and this bacteria-resistant activity is clearly reduced by the co-injection of anti-ZRANB2 antibody, we thus propose that ZRANB2 may defend early embryos \textit{in vivo} against pathogenic attacks by the same mechanisms via binding to and lysing invading pathogens.

Fishes represent basal vertebrates that have an innate and adaptive system comparable with that of mammals. Currently, little information is available regarding the role of ZRANB2 in mammalian embryonic development, although it has been shown to be a developmentally regulated factor expressed in juxtaglomerular cells (37). Given the high conservation rate of ZRANB2 from fish to mammals, we thus speculate that mammalian ZRANB2 may also play a similar role in early development. However, this deserves further study in the future.

Proteins are built as chains of amino acids, which then fold into unique three-dimensional shapes; and the final folded forms of proteins are well adapted for their functions. It is notable that the N-terminal 37 residues, especially those 26 residues comprising the first ZnF\_RBZ domain \textit{per se}, are the core struc-

![FIGURE 9. Antimicrobial activity of rZRANB2 and its truncated peptides against \textit{A. hydrophila}. a, inhibition of rZRANB2 against \textit{A. hydrophila}. b, inhibition of Z_{1/37} against \textit{A. hydrophila}. c, inhibition of Z_{38/198} against \textit{A. hydrophila}. d, inhibition of Z_{11/37} against \textit{A. hydrophila}. Each point in the graph represents the mean $\pm$ S.D. ($n = 3$). The data are from three independent experiments performed in triplicate. The bars represent the mean $\pm$ S.D.](image1)

![FIGURE 10. The \textit{in vivo} bioactivity of Z_{1/37}, Z_{11/37}, and Z_{38/198}. The early (8-cell stage) embryos were first microinjected with PBS, BSA, anti-\textbeta\-actin antibody (AcAb), anti-human ZRANB2 antibody (ZRANB2Ab), Z_{1/37}, Z_{11/37}, and Z_{38/198} and then challenged by injection with live \textit{A. hydrophila}. The development of the embryos was observed, and the cumulative mortality rate was calculated at 24 h after injection. **, extremely significant difference ($p < 0.01$). All data were expressed as mean values $\pm$ S.D. ($n = 3$). The data are from three independent experiments performed in triplicate. The bars represent the mean $\pm$ S.D.](image2)
ture contributing to the antimicrobial activity of ZRANB2. The first ZnF_RBZ domain of zebrafish ZRANB2 has a \( Zn^{2+}\)-binding site, whereas the second domain does not, as revealed by our three-dimensional structure prediction (Fig. 3b). This may be the reason that the N-terminal 37 residues containing the first ZnF_RBZ possess antibacterial activity, but the C-terminal 161 residues containing the second ZnF_RBZ do not. It is also notable that the antibacterial activity against *E. coli*, *V. anguilarum*, and *A. hydrophila* and the affinity to LPS co-exist in both \( Z_{1/37} \) and \( Z_{11/37} \) as well as rZRANB2, but neither the antibacterial activity nor the affinity to LPS are present in \( Z_{38/198} \), suggesting the presence of a correlation between antibacterial activity and LPS binding activity. Possibly, this correlation indicates that the functional sites of rZRANB2, \( Z_{1/37} \) and \( Z_{11/37} \) may be involved simultaneously in multiple activities, including binding to microbial signature molecule LPS and destabilizing/disrupting bacterial cell membranes.

In conclusion, this study is the first to demonstrate that ZRANB2 is a novel maternal LPS-binding protein associated with the antibacterial defense of early embryos in zebrafish; and then it elucidates that ZRANB2 is a PRR capable of identifying LPS and an antibacterial effector molecule capable of inhibiting the growth of Gram-negative bacteria. Moreover, our study reveals that the N-terminal 26 residues with the ZnF_RBZ domain are critical for ZRANB2 antibacterial activity. This work also provides a new angle for the study of the immunological roles of zinc finger proteins, which are widely distributed in various animals.

**Author Contributions**—S. Z. and X. W. designed the experiments and wrote the paper. X. W. and X. D. performed the experiments. X. W., X. D., H. L., and S. Z. analyzed the data. All authors approved and wrote the paper. X. W. and X. D. performed the experiments.

**Acknowledgments**—We are grateful to Mingzhuan Zhu for technical aid in flow cytometry and to Yunsi Kang, Haibo Xie, and Dong Feng for help with immunohistochemistry.

**References**


